Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This phase I pilot study aims to define the safety of a combined treatment of bevacizumab and
whole brain radiation therapy for the treatment of patients with brain metastasis of solid
tumors. If this therapeutic scheme confirms it's safety profile, the investigators can
expect:
- first, to allow that all patients can receive bevacizumab for their advanced and/or
metastatic cancer if necessary, even in case of brain metastasis.
- Secondly, if this trial confirm a synergic effect of the combination of angiogenesis
inhibitors and brain radiotherapy for local control of brain metastasis, an improvement
of the therapeutic results for these patients which have a poor hope of survival and for
which none innovative approach is currently suggested.
Moreover, the investigators hope that the analysis of the different data of MRI evaluation -
morphological and functional - will allow better definition of radiological evaluation of the
therapeutic effect of angiogenesis inhibitors on brain metastasis.
Phase:
Phase 1
Details
Lead Sponsor:
Centre Francois Baclesse
Collaborators:
Institut Curie National Cancer Institute, France Roche Pharma AG